FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent(r) (alirocumab) Injection for Patients with Hypercholesterolemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent(r) (alirocumab) Injection for Patients with Hypercholesterolemia

RBC Capital Comments on Regeneron (REGN) Following 'Unexpectedly Cautious' Adcom

June 10, 2015 7:09 AM EDT

RBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) with a price target of $543. Yesterday an FDA panel recommended the approval of Regeneron and Sanofi's (NYSE: SNY) investigational therapy Praluent. Despite the favorable recommendation, analyst Adnan Butt described the panel as "unexpectedly cautious," though he still expects a broad, if not the broadest, label.

"Despite the overall recommendation for approval, the panels caution around breadth of label, safety, and outcomes can create an overhang. We... More